Name: Amgen (AMGN) Sales Higher After Obesity Drug Results
Uploaded: 2024-05-03T16:36:02.231-05:00
Duration: 3 min 49 s
Description: Amgen (AMGN) sales are higher after early results from a study of an obesity drug. Renita Young discusses this as the Amgen CEO is “very encouraged” by the results of the obesity drug study. Tune in to find out more about the stock market today.

Morning Movers

Opening Bell With Nicole Petallides

Morning Trade Live

Trading 360

Fast Market

Next Gen Investing

The Watch List

Market On Close

Market Overtime

Inside the Mind of a Trader

Your First Trade

The Wrap

Liz Ann Live

Schwab 2026 Outlook

<p>Sam Vadas takes traders beyond the headlines with a sharp focus on the macro drivers, sector rotations, and global forces shaping the day’s market action. From breaking down U.S. and international economic data to analyzing sector performance and cross-asset moves, Morning Trade Live delivers the context traders need to understand the “why” behind early trading activity.</p>

Daily insights for every investor

Schwab Network's Newsletters

<p>Amgen (AMGN) sales are higher after early results from a study of an obesity drug. Renita Young discusses this as the Amgen CEO is “very encouraged” by the results of the obesity drug study. Tune in to find out more about the stock market today.</p>

Amgen (AMGN) Sales Higher After Obesity Drug Results

Expert commentary about top moving stocks, sectors, and commodities, along with CEO and analyst interviews.

Market News